Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Alectinib - Study

Preclinical

HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

ALK-Positive Non-Small Cell Lung CancerActive, not recruiting

ALK-Positive Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

ALK-Positive Non-Small Cell Lung Cancer

NCT05987956

Clinical

Trials by Indication[1]

ALK-positive Non-small Cell Lung Cancer1 trial

Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.

Active, not recruiting·HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·Preclinical·NCT05987956·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Alectinib - Study. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Alectinib - Study. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Related News